200 related articles for article (PubMed ID: 19584227)
1. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Raynaud FI; Eccles SA; Patel S; Alix S; Box G; Chuckowree I; Folkes A; Gowan S; De Haven Brandon A; Di Stefano F; Hayes A; Henley AT; Lensun L; Pergl-Wilson G; Robson A; Saghir N; Zhyvoloup A; McDonald E; Sheldrake P; Shuttleworth S; Valenti M; Wan NC; Clarke PA; Workman P
Mol Cancer Ther; 2009 Jul; 8(7):1725-38. PubMed ID: 19584227
[TBL] [Abstract][Full Text] [Related]
2. Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Workman P; Clarke PA; Raynaud FI; van Montfort RL
Cancer Res; 2010 Mar; 70(6):2146-57. PubMed ID: 20179189
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.
Burrows N; Williams J; Telfer BA; Resch J; Valentine HR; Fitzmaurice RJ; Eustace A; Irlam J; Rowling EJ; Hoang-Vu C; West CM; Brabant G; Williams KJ
Oncotarget; 2016 Sep; 7(39):63106-63123. PubMed ID: 27527858
[TBL] [Abstract][Full Text] [Related]
4. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Koul D; Shen R; Kim YW; Kondo Y; Lu Y; Bankson J; Ronen SM; Kirkpatrick DL; Powis G; Yung WK
Neuro Oncol; 2010 Jun; 12(6):559-69. PubMed ID: 20156803
[TBL] [Abstract][Full Text] [Related]
5. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.
Pasqua AE; Sharp SY; Chessum NEA; Hayes A; Pellegrino L; Tucker MJ; Miah A; Wilding B; Evans LE; Rye CS; Mok NY; Liu M; Henley AT; Gowan S; De Billy E; Te Poele R; Powers M; Eccles SA; Clarke PA; Raynaud FI; Workman P; Jones K; Cheeseman MD
J Med Chem; 2023 Apr; 66(8):5907-5936. PubMed ID: 37017629
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Bicyclic Pyrazoles as Potent PIP5K1C Inhibitors.
Ochiai K; Seto S; Yajima M; Namie R; Hashimoto N; Fujita M; Yokoyama A; Suezawa T; Matsui H; Tomizawa S; Ishibashi Y; Tanaka Y; Yajima M; Nagasawa M; Ando N
ACS Med Chem Lett; 2024 May; 15(5):684-690. PubMed ID: 38746884
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
8. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
[TBL] [Abstract][Full Text] [Related]
9. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR
Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236
[TBL] [Abstract][Full Text] [Related]
10. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
[TBL] [Abstract][Full Text] [Related]
11. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
Berndt A; Miller S; Williams O; Le DD; Houseman BT; Pacold JI; Gorrec F; Hon WC; Liu Y; Rommel C; Gaillard P; Rückle T; Schwarz MK; Shokat KM; Shaw JP; Williams RL
Nat Chem Biol; 2010 Feb; 6(2):117-24. PubMed ID: 20081827
[TBL] [Abstract][Full Text] [Related]
12. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
[TBL] [Abstract][Full Text] [Related]
13. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
Thorpe LM; Yuzugullu H; Zhao JJ
Nat Rev Cancer; 2015 Jan; 15(1):7-24. PubMed ID: 25533673
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Fritsch C; Huang A; Chatenay-Rivauday C; Schnell C; Reddy A; Liu M; Kauffmann A; Guthy D; Erdmann D; De Pover A; Furet P; Gao H; Ferretti S; Wang Y; Trappe J; Brachmann SM; Maira SM; Wilson C; Boehm M; Garcia-Echeverria C; Chene P; Wiesmann M; Cozens R; Lehar J; Schlegel R; Caravatti G; Hofmann F; Sellers WR
Mol Cancer Ther; 2014 May; 13(5):1117-29. PubMed ID: 24608574
[TBL] [Abstract][Full Text] [Related]
15. [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
Cawthorne C; Burrows N; Gieling RG; Morrow CJ; Forster D; Gregory J; Radigois M; Smigova A; Babur M; Simpson K; Hodgkinson C; Brown G; McMahon A; Dive C; Hiscock D; Wilson I; Williams KJ
Mol Cancer Ther; 2013 May; 12(5):819-28. PubMed ID: 23427298
[TBL] [Abstract][Full Text] [Related]
16. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
17. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
18. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Chou B; Halladay JS; Olivero AG; Rudewicz PJ; Tian Q; Wong S; Zhang X
Xenobiotica; 2011 Dec; 41(12):1088-99. PubMed ID: 21838594
[TBL] [Abstract][Full Text] [Related]
20. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
